Thomas Jurgensen

Molecular Biosystems, Inc. develops, makes and sells ultrasound contrast imaging agents. The company was founded by Kenneth J. Widder, Richard H. Tullis, Drew E. Senyei and Lyle J. Arnold and is headquartered in San Diego, CA.

Allylix, Inc. develops terpene products for flavor and fragrance, food ingredients, pharmaceuticals, agricultural, and biofuels markets. The company was founded by Joseph Chappel, Thomas E. Jurgensen, and Joseph Noel on January 4, 2005 and is headquartered in Lexington, KY.

CLC Entertainment Studios, Inc. develops, produces, and distributes entertainment projects in the areas of film, television, and Broadway plays. The company was founded by Cathy Lee Crosby and is headquartered in Santa Monica, CA.

Merchant & Gould PC provides legal services. It focuses on appellate, licensing, litigation, mechanical, copyright, and trademarks. The company was founded in 1900 and is headquartered in Minneapolis, MN.

Inverseon, Inc. is a private company developing a re-profiled beta blocker for the treatment of asthma and COPD. Inverseon’s scientific approach, “Paradoxical Pharmacology”, is based on observations that chronic effects of inverse agonist drugs are completely opposite to their acute effects. A similar paradigm shift occurred in the late 1990’s with the approval of the first beta blocker for congestive heart failure, a disease state where the drug was also originally contraindicated. Inverseon’s scientific founder, Professor Richard Bond, identified the mechanism of action as inverse agonism at the beta adrenergic receptor and hypothesized that this observation represented a general pharmacological phenomenon and identified asthma as another disease to target. To date, the company has achieved a number of important milestones: completing two open-label Phase 2a studies demonstrating a dose-response, a comment in The Lancet in 2009 highlighting the published human clinical trial, and 2009 issuance of their first U.S. patent.